Daiichi Sankyo Co., Ltd. has entered a definitive merger agreement to acquire Ambit Biosciences in a transaction valued at as much as $410 million. Ambit is a biopharma company focused on the discovery and development of medicines to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting enzymes behind those diseases. Ambit’s lead drug candidate, quizartinib, is currently in Phase III trials in patients with acute myeloid leukemia (AML) who express a genetic m...